睿知中国医院研究地图
候选清单

正在招募食管鳞状细胞癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验。牵头方不是本站收录的医院;本站收录的 28 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 28

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心济宁医学院附属医院Affiliated Hospital of Jining Medical University济宁医院页面
  2. 研究中心安徽省肿瘤医院Anhui Provincial Cancer Hospital合肥医院页面
  3. 研究中心安阳市肿瘤医院Anyang Tumor Hospital安阳医院页面
  4. 研究中心山东第一医科大学附属中心医院(济南市中心医院)Central Hospital Affiliated to Shandong First Medical University济南医院页面
  5. 研究中心福建医科大学附属第一医院First Affiliated Hospital of Fujian Medical University福州医院页面
  6. 研究中心河南科技大学第一附属医院First Affiliated Hospital of Henan University of Science and Technology洛阳医院页面
  7. 研究中心河南医药大学第一附属医院First Affiliated Hospital of Xinxiang Medical University新乡医院页面
  8. 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
  9. 研究中心吉林大学第一医院First Hospital of Jilin University长春医院页面
  10. 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
  11. 研究中心广西医科大学附属肿瘤医院Guangxi Medical University Cancer Hospital南宁医院页面
  12. 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
  13. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  14. 研究中心湖北省肿瘤医院Hubei Cancer Hospital武汉医院页面
  15. 研究中心吉林省肿瘤医院Jilin Cancer Hospital长春医院页面
  16. 研究中心辽宁省肿瘤医院Liaoning Cancer Hospital & Institute沈阳医院页面
  17. 研究中心临沂市肿瘤医院Linyi Cancer Hospital临沂医院页面
  18. 研究中心江苏省苏北人民医院Northern Jiangsu People's Hospital扬州医院页面
  19. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  20. 研究中心安徽医科大学第二附属医院Second Affiliated Hospital of Anhui Medical University合肥医院页面
  21. 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
  22. 研究中心汕头大学医学院附属医院Shantou University Medical College hospitals汕头医院页面
  23. 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
  24. 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
  25. 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
  26. 研究中心四川大学华西医院West China Hospital成都医院页面
  27. 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面
  28. 研究中心厦门大学附属中山医院Zhongshan Hospital, Xiamen University厦门医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06644781,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 4

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(4 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Has histologically or cytologically documented unresectable locally advanced or metastatic ESCC according to American Joint Committee on Cancer 8th edition staging system on ESCC.

    入选标准第 2 条

  3. Has disease progression post a platinum-based chemotherapy and an ICI treatment per global or local guidelines, with a maximum of 1 prior line of systemic therapy for unresectable advanced or metastatic ESCC.

    入选标准第 3 条

    Has received prior treatment with orlotamab, enoblituzumab, or other B7-H3 targeted agents, including I-DXd.

    排除标准第 1 条

  4. Has an ECOG PS of 0 or 1 within 7 days prior to Cycle 1 Day 1.

    入选标准第 6 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06644781,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Participants aged ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is >18 years old).
  2. Has histologically or cytologically documented unresectable locally advanced or metastatic ESCC according to American Joint Committee on Cancer 8th edition staging system on ESCC.
  3. Has disease progression post a platinum-based chemotherapy and an ICI treatment per global or local guidelines, with a maximum of 1 prior line of systemic therapy for unresectable advanced or metastatic ESCC.
  4. The participant must provide adequate baseline tumor samples with sufficient quantity and quality of tumor tissue content as defined in the Laboratory Manual.
  5. Has at least 1 measurable lesion on computed tomography (CT)/magnetic resonance imaging (MRI) according to RECIST v1.1 as assessed by the investigator. Measurable lesions should not be from a previously irradiated site. If the lesion at a previously irradiated site is the only selectable target lesion, a radiological assessment showing significant progression of the irradiated lesion should be provided by the investigator.
  6. Has an ECOG PS of 0 or 1 within 7 days prior to Cycle 1 Day 1.

排除标准:Exclusion Criteria:

  1. Has received prior treatment with orlotamab, enoblituzumab, or other B7-H3 targeted agents, including I-DXd.
  2. Has received any topoisomerase inhibitor.
  3. Has histologically or cytologically confirmed adenosquamous carcinoma subtype.
  4. Is ineligible to all the chemotherapies in the comparator arm due to prior progression or intolerance.
  5. Has tumor invasion into organs located adjacent to the esophageal disease site (eg, aorta or respiratory tract) at an increased risk of bleeding or fistula as assessed by the investigator.
  6. Clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis, defined as untreated or symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. Subjects with clinically inactive or treated brain metastases who are asymptomatic (ie, without neurologic signs or symptoms and not requiring treatment with corticosteroids or anticonvulsants) may be included in the study. Subjects must have a stable neurologic status and discontinue corticosteroid usage for at least 2 weeks prior to Screening.
  7. Has any of the following within the past 6 months: cerebrovascular accident, transient ischemic attack, other arterial thromboembolic event, or pulmonary embolism.
  8. Has a clinically significant corneal disease.
  9. Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required corticosteroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at Screening.
  10. Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses, including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months of the study randomization, severe asthma, chronic obstructive pulmonary disease [COPD], restrictive lung disease, pleural effusion, etc), and potential pulmonary involvement caused by any autoimmune, connective tissue, or inflammatory disorders (eg, rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc), prior pneumonectomy, or requirement for supplemental oxygen.
  11. Is on chronic steroid treatment (dose of 10 mg daily or more prednisone equivalent), except for low-dose inhaled steroids (for asthma/COPD), topical steroids (for mild skin conditions), or intra-articular steroid injections.

引自 ClinicalTrials.gov, NCT06644781, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06644781,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06644781